Kenvue Inc

1KVUE

Company Profile

  • Business description

    Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.

  • Contact

    199 Grandview Road
    SkillmanNJ08558
    USA

    T: +1 908 874-1200

    https://www.kenvue.com

  • Sector

    Consumer Defensive

    Stock type

    Defensive

  • Industry

    Household & Personal Products

    Fiscal Year End

    31 December 2025

    Employees

    22,000

Stocks News & Analysis

stocks

Ask the analyst: Are Qantas shares a value trap?

Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks

Palantir earnings: Blockbuster growth amid high expectations

We raise our fair value estimate off the back of earnings.
stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,111.1082.300.91%
CAC 407,621.0410.97-0.14%
DAX 4023,846.0788.380.37%
Dow JONES (US)44,111.7461.90-0.14%
FTSE 1009,142.7314.430.16%
HKSE24,915.8613.330.05%
NASDAQ20,916.55137.03-0.65%
Nikkei 22540,794.86245.320.60%
NZX 50 Index12,880.163.120.02%
S&P 5006,299.1930.75-0.49%
S&P/ASX 2008,843.7073.300.84%
SSE Composite Index3,631.9314.330.40%

Market Movers